Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different
ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and
help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy work in
different ways to stop the growth of cancer cells, either by killing the cells or by stopping
them from dividing. Giving rituximab together with combination chemotherapy may kill more
cancer cells.
PURPOSE: This phase II trial is studying how well giving rituximab together with combination
chemotherapy works in treating patients with newly diagnosed stage II, stage III, or stage IV
Hodgkin's lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins